SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Lupin - Quaterly Results

03 Feb 2022 Evaluate
The revenue for the December 2021 quarter is pegged at Rs. 27319.90 millions against Rs. 28024.70 millions recorded during the year-ago period.Net Profit for the quarter ended December 2021 zoomed to 143.04% from Rs. 2182.50 millions to Rs. 5304.40  millions.The company reported a degrowth in operating Profit to 2437.00 millions from 4296.50 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 27319.90 28024.70 -2.51 89162.80 85401.50 4.40 110559.30 110256.60 0.27
Other Income 372.50 222.20 67.64 1636.10 815.20 100.70 1290.90 4751.90 -72.83
PBIDT 2437.00 4296.50 -43.28 -910.20 16820.30 -105.41 21731.50 23828.00 -8.80
Interest 158.10 105.00 50.57 488.90 283.10 72.70 406.20 525.90 -22.76
PBDT 2278.90 4191.50 -45.63 -1399.10 16537.20 -108.46 21325.30 15710.00 35.74
Depreciation 1279.10 1270.80 0.65 3831.70 3778.20 1.42 5028.30 5187.50 -3.07
PBT 999.80 2920.70 -65.77 -5230.80 12759.00 -141.00 16297.00 10522.50 54.88
TAX -4304.60 738.20 -683.12 -3702.70 3336.40 -210.98 3710.80 3247.00 14.28
Deferred Tax -5455.40 -80.60 6668.49 -3725.70 -154.40 2313.02 82.30 -373.50 -122.03
PAT 5304.40 2182.50 143.04 -1528.10 9422.60 -116.22 12586.20 7275.50 72.99
Equity 908.40 907.00 0.15 908.40 907.00 0.15 907.40 906.00 0.15
PBIDTM(%) 8.92 15.33 -41.82 -1.02 19.70 -105.18 19.66 21.61 -9.05

Lupin Share Price

2382.15 38.75 (1.65%)
06-May-2026 09:48 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1831.50
Dr. Reddys Lab 1283.40
Cipla 1339.00
Zydus Lifesciences 919.80
Lupin 2382.15
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×